Upstream bio inc UPB.US 總覽分析
UPB 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
UPB 近期報酬表現
-4.00%
Upstream bio inc
3.56%
同產業平均
1.47%
S&P500
與 UPB 同產業的標的表現
- CGEM Cullinan therapeutics inc價值 2 分趨勢 2 分波段 5 分籌碼 3 分股利 1 分查看更多
UPB 公司資訊
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.